In this study, we quantitatively evaluated three immunohistochemical markers, LC3, p62 and TDP-43, for their diagnostic utility in differentiating IBM from PM and intermediate T cell-rich inflammatory myopathies, PM-COX and pIBM. The gene discussed is MAP1LC3A; the disease is inclusion body myositis.